Refinements of the IPSS-R beyond the IPSS
| 1. New marrow blast categories |
| ≤ 2%, > 2%-< 5%, 5%-10%, > 10%-30% |
| 2. Refined cytogenetic abnormalities and risk groups |
| 16 (vs 6) specific abnormalities, 5 (vs 3) subgroups |
| 3. Evaluation of depth of cytopenias |
| Clinically and statistically relevant cutpoints used |
| 4. Inclusion of differentiating features* |
| Age, Performance Status, serum ferritin, LDH; β2-microglobulin† |
| 5. Prognostic model with 5 (vs 4) risk categories |
| Improved predictive power |
| 1. New marrow blast categories |
| ≤ 2%, > 2%-< 5%, 5%-10%, > 10%-30% |
| 2. Refined cytogenetic abnormalities and risk groups |
| 16 (vs 6) specific abnormalities, 5 (vs 3) subgroups |
| 3. Evaluation of depth of cytopenias |
| Clinically and statistically relevant cutpoints used |
| 4. Inclusion of differentiating features* |
| Age, Performance Status, serum ferritin, LDH; β2-microglobulin† |
| 5. Prognostic model with 5 (vs 4) risk categories |
| Improved predictive power |